# Patent

## Title
Method for screening a potential modulator compound of a taste receptor

## Abstract

A method for screening a potential modulator compound of a taste receptor wherein use is made of a BRET technique.

## Background
This application is a National Stage application filed under Rule 371 based upon PCT/EP2010/068399 filed Nov. 29, 2010 which claims priority to EP application 09177694 filed Dec. 2, 2009.
FIELD OF THE INVENTION
The invention relates to a method for screening a potential modulator compound of a taste receptor, wherein use is made of a BRET technique.
BACKGROUND OF THE INVENTION
Flavour is part of our primary sensory system that controls food intake1 so that we consume pleasant (i.e. nutritional food) and avoid unpleasant food (containing potential toxins). Flavour is a sensation formed from visual, taste, aroma and mouth feel inputs. However, food choice and the amount we consume seem to be driven more by three of the five basic tastes (salt, sweet and umami) and is less affected by the other flavour attributes. Foods containing these attributes tend to be the ones preferred by humans as well as most mammals; in that context umami serves as a marker for proteins and sweetness for carbohydrates.
Recently the receptors involved in the detection of these taste modalities have been identified and cloned2-4, thus making it possible to investigate activation of taste receptors in vitro. The receptors for sweet, umami and bitter belong to the class of G-protein coupled receptors (GPCRs), whereas saltiness and sourness are most likely detected by ion channels.
Sweetness is sensed by the heterogeneous receptor dimer T1R2/T1R3, whereas umami is primarily detected by the T1R1/T1R3 receptor2, although other receptors have also been implicated to be involved in umami as well5.
Various cellular systems can be used for measuring in vitro receptor activation with good correlation to the in vivo sensory perception, including heterologous expression of taste receptors in mammalian cell lines like HEK293 cells2, 6-9. The currently available functional in vitro screening systems usually make use of promiscuous G-proteins such as Gα15, Gα16 or chimeras of these G-proteins with various adaptations of the C-terminal domain; this will direct the signalling cascades of receptors of interest to PLC (phospholipase C) and release of intracellular calcium. Although this approach has been very successful for investigating pure compounds, it has proven to be more difficult for testing extracts or complex samples: due to the universal nature of the G-proteins they are not only able to couple to the recombinant receptors (over)expressed in the screening cell lines, but also to many receptors which are endogenously present at low levels. This can result in unspecific calcium signals induced by agonists present in natural mixtures activating these endogenous receptors. Moreover, extracts or complex test samples often also contain substances, which elevate intracellular calcium by other means than via GPCRs, and these signals will be indistinguishable from receptor-induced calcium release. The high unspecific background signal observed for most natural mixtures prevents direct screening of these samples without extensive fractionation procedures. It is to be noted that the use of such extracts or complex samples is quite common when evaluating food material for example.
Therefore there is still a need for an improved screening method for a potential modulator compound of a taste receptor, wherein this method does not have each of the drawbacks of existing methods.
DESCRIPTION OF THE INVENTION
In a first aspect there is provided a method for screening a potential modulator compound of a taste receptor, wherein use is made of a BRET (Bioluminescence Resonance Energy Transfer)(10, 11) technique. Each feature of this method is extensively defined below.
A preferred method comprises the following steps:


    
    
        a) providing a cell expressing a taste receptor fused to a luminescent protein such as a luciferase protein and a fluorescent protein fused to a β-arrestin or inducing their expression,
        b) challenging the cell obtained in step a) with a potential modulator compound and,
        c) comparing a BRET signal of the cell obtained in step b) with a BRET signal of the cell obtained in b) in the absence of the potential modulator.

Alternatively, in the first aspect the invention provides a method for identifying a compound which modulates a taste receptor, wherein the method comprises the steps of: (a) providing a cell expressing (i) a taste receptor fused to a luminescent protein and (ii) a fluorescent protein fused to a β-arrestin; (b) contacting the cell with a potential modulator compound and determining the BRET signal; and, (c) comparing the BRET signal obtained in step (b) with a BRET signal obtained from the cell in the absence of the potential modulator compound, wherein a difference between the BRET signal as obtained in (b) and the BRET signal obtained in the absence of the potential modulator compound, is indicative of the potential modulator compound being a compound which modulates a taste receptor.

    
    


Our invention uses a BRET technique or assay which confers more specificity to a method of the invention: a taste receptor of interest is fused with a donor luminescent protein such as a luciferase protein, no other cellular components can influence a signal originating from said receptor and cause a BRET signal. This is of special interest with respect to natural mixtures often available for screening in order to identify a potential modulator compound of a taste receptor: neither components activating endogenous receptors nor substances previously causing unspecific elevation of intracellular calcium via other pathways are able to cause a BRET signal. The read-out window is solely focussed on the receptor-luminescent fusion protein, thus making this method exceptionally useful for directly investigating receptor activation using non-purified, crude extracts with high specificity.
A method of the invention is based on the ability of a taste receptor being a GPCRs (G Protein Coupled Receptors) to translocate β-arrestin upon receptor stimulation and utilises a BRET assay for measuring receptor-β-arrestin interaction by measuring energy transfer between fusion proteins containing the energy donor (a luminescent protein such as a luciferase) and the energy acceptor protein (a fluorophore, typically a fluorescent protein), which absorbs light at a given wavelength and reemits light at a longer wavelength10. In the case of GPCR activation assay, a luminescent protein such as a luciferase is fused to the C-terminal of the receptor, and a fluorescent protein to a β-arrestin. If a receptor is activated, cytosolic β-arrestin is recruited to the plasma membrane and targets the receptor for internalisation. During the interaction of β-arrestin/fluorescent protein with the luminescent protein-fused receptor, donor and acceptor proteins are in close proximity and will induce a BRET signal.
A BRET technique is therefore a technique or assay which can generate a signal or a BRET signal, said signal being an energy transfer between a taste receptor fused to a luminescent protein and a fluorescent protein and said signal reflecting the activation of said taste receptor due to the presence of a potential modulator compound.
Step a) of a method of the invention provides a cell expressing a taste receptor fused to a luminescent protein such as a luciferase protein and a fluorescent protein fused to a β-arrestin or inducing their expression. Step a) of a method of the invention can also provide a cell expressing (i) a taste receptor fused to a luminescent protein and (ii) a fluorescent protein fused to a β-arrestin.
A taste receptor may be any receptor known to be associated with taste in the mouth of a human. A taste receptor may also be any receptor which is later discovered as being involved in a taste perception. A taste receptor may be expressed in the tongue: a MSG (Mono Sodium Glutamate) or umami receptor, a sweet receptor, a bitter receptor or a fat receptor. A receptor known to be involved in sweet perception is a heterodimer comprising two subunits T1R2 (Taste 1 Receptor 2) and T1R3 (Taste 1 Receptor 3). A receptor known to be involved in umami perception is another heterodimer comprising two subunits T1R1 (Taste 1 Receptor 1) and T1R3. Another MSG or umami receptor is composed of one or more subunits of mGluR4 (a or c) (Metabotropic Glutamate Receptor 4 (a or c)). A bitter receptor is composed of one or more subunits of a TAS2 (Taste 2) receptor. A fatty acid receptor is composed of one or more subunits of GPR120 (G-Protein coupled receptor 120). A preferred nucleic acid sequence representing a human T1R1 is SEQ ID NO:1. A corresponding preferred amino acid sequence representing a human T1R1 protein is represented by SEQ ID NO:2. A preferred nucleic acid sequence representing a human T1R3 is SEQ ID NO:3. A corresponding preferred amino acid sequence representing a human T1R3 protein is represented by SEQ ID NO:4.
Within the context of the invention, a taste receptor may also be a receptor involved in nutrient/fatty acid sensing in the gut of a human. Such receptors include: the calcium-sensing receptor, the G protein-coupled receptor family C, group 6, subtype A (GPRC6A), the taste receptor dimer T1R1/T1R3, which is sensing L-alpha-amino acids, the carbohydrate-sensing T1R2/T1R3 receptor dimer, the proteolytic degradation product sensor GPR93 (also termed GPR92), and the free fatty acid (FFA) sensing receptors FFA1, FFA2, FFA3, GPR84, and GPR1205. Each of the receptor identified in Table 3 may be used in a method of the invention. A preferred nucleic acid molecule encoding each of these receptors is given in the sequence listing. A corresponding preferred encoded receptor is also given in the sequence listing (see also Table 3).
A method of the invention is exemplified using a taste receptor comprising a T1R1 and a T1R3 subunit and using a luciferase as a luminescent protein. However, the skilled person will understand that the invention is not limited to a method using said heterodimer and this luminescent protein. The invention provides a cell expressing a taste receptor, preferably a T1R1, T1R3 heterodimer. Said taste receptor is preferably functional. It means that in a screening method of the invention carried out without adding a potential modulator, a detectable BRET signal is present when a substance known to activate this taste receptor is added to said cell. For each taste receptor, such substance is known. Examples of such substances, i.e. agonists are identified in Table 1.
The invention also provides a step a) wherein a cell is provided expressing a taste receptor fused to a fluorescent protein and a luminescent protein such as a luciferase protein fused to a β-arrestin or inducing their expression. Each feature defined herein for a luminescent protein such as a luciferase protein when fused to a taste receptor also holds for a luminescent protein such as a luciferase protein when fused to a β-arrestin. Each feature defined herein for a fluorescent protein when fused to a β-arrestin also holds for a fluorescent protein when fused to a luminescent protein such as a luciferase protein. Thus the invention also provides a method wherein the taste receptor is fused to a fluorescent protein and the β-arrestin to a luminescent protein. More generally, the skilled person will understand that any embodiment of the invention wherein a luminescent protein is fused to the taste receptor and a fluorescent protein is fused to the β-arrestin can be replaced by an otherwise identical embodiment wherein a fluorescent protein is fused to the taste receptor and a luminescent protein is fused to the β-arrestin.
The invention identifies a preferred nucleic acid molecule represented by a nucleic acid sequence, respectively an encoded protein represented by an amino acid sequence to be used to obtain a cell for use in a method of the invention. However, each of the nucleic acid sequence as identified herein may be replaced by a naturally occurring form, a variant containing a SNP (Single Nucleotide Polymorphism), an alternatively spliced form, a combination of form, or any functional variant known in the art. A nucleic acid molecule as defined herein should be functional when expressed in a cell as earlier explained herein. A variant of a nucleic acid sequence may be a fragment of this nucleic acid sequence. A preferred variant contains a silent mutation. Alternatively, or in combination, a nucleic acid sequence variant may also be obtained by introduction of a nucleotide substitution which does not give rise to another amino acid sequence, but which corresponds to the codon usage of the host cell wherein said nucleic acid sequence will be expressed. Preferably, a nucleic acid sequence variant is such that starting from any one of the nucleic acid sequence as earlier defined herein, one or more nucleotides from the 5 and/or 3′ end have been deleted. Alternatively or in combination, a nucleic acid sequence variant is preferably a nucleic acid sequence isolated from another organism and/or another family member of the nucleic acid sequence as earlier defined herein. All these variants can be obtained in a typical approach, using cDNA or genomic libraries from a chosen species, e.g. mammalian species such as humans. The library can be subsequently screened with one of the nucleic acid sequences as earlier defined herein or part thereof by hybridization under stringent conditions. Stringent conditions mean prehybridization and hybridization at 42° C. in 5×SSPE, 0.3% SDS, 200 pg/ml sheared and denatured salmon sperm DNA, and 50% formamide. Subsequently, the hybridization reaction is washed three times for 30 minutes each using 2×SSC, 0.2% SDS and 75° C. Alternatively or in combination, a nucleic acid sequence variants may be obtained by searching for amino acid identities and/or similarities in databases and synthesis of a nucleic acid sequence encoding an suitable amino acid sequence identified in the search.
Human is a preferred species. According to another preferred embodiment, a nucleic acid sequence variant is an allelic variant. An allelic variant denotes any of two or more alternative forms of a gene occupying the same chromosome locus. Allelic variation arises naturally through mutation, and may result in phenotypic polymorphism within populations. According to another preferred embodiment, a nucleic acid sequence variant differs from any of the nucleic acid sequences as earlier defined herein by virtue of the degeneracy of the genetic code.
More explanation as to the nucleic acid molecule used is given in the section entitled “Nucleic acid molecule defined by a SEQ ID NO and Sequence identity”. In a preferred embodiment, a nucleic acid molecule used originates from a human. More preferably, a nucleic acid molecule as defined in this preferred embodiment is for functional expression in a mammalian, even more preferably a human cell. The use of a sequence, which is highly homologous (identity of at least 85%) with a human sequence is attractive since we may expect this nucleic acid molecule will be expressed and functional in mammalian, preferably a human cell. Furthermore, this sequence is so highly homologous with a human sequence that we expect that the cell type hence prepared will mimic human taste more efficiently than cell type prepared with a sequence having a lower identity to a human sequence. Even more preferably, the identity as defined earlier herein is 85% or more, even more preferably 90% or more, even more preferably 91% or more, even more preferably 92% or more, even more preferably 93% or more, even more preferably 94% or more, even more preferably 95% or more, even more preferably 96% or more, even more preferably 97% or more, even more preferably 98% or more, even more preferably 99% or more, and most preferably 100%.
In the invention, a nucleic acid molecule encoding a taste receptor or a subunit thereof is fused to a luminescent protein such as a luciferase protein. In a preferred embodiment, a luminescent protein is a luciferase protein. A luminescent protein such as a luciferase protein is preferably fused at the C terminal part of the receptor which is its intracellular part. The skilled person will understand that a luminescent protein such as a luciferase protein may be fused anywhere in the intracellular part of a taste receptor. However, the protein hence obtained should be still functional; i.e. activatable. Therefore when a luminescent protein such as a luciferase protein has been fused somewhere in the intracellular part of a taste receptor, it is preferred that such a protein hence obtained which is preferably a recombinant protein is tested as to its functionality. In a preferred embodiment, a luminescent protein such as a luciferase protein is fused at the end of the C terminal part of a taste receptor or as close possible to the end of the C terminal part of said taste receptor. As close possible to the end of the C terminal part of said taste receptor preferably means that the first amino acid of a luminescent protein such as a luciferase protein is present at the place corresponding to the last amino acid of the C terminal part of a taste receptor or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 amino acid before the last amino acid of the C terminal part of a taste receptor. A luciferase may be a Firefly luciferase or may be from any Renilla species. A preferred nucleic acid molecule encoding a luciferase has been improved with humanized codon in order to improve its expression level in a mammalian cell. A more preferred nucleic acid molecule encoding a preferred luciferase is given as SEQ ID NO:77 A preferred encoded luciferase protein is identified as SEQ ID NO:78 The skilled person knows how to fuse two nucleic acid molecules in frame. In the case of a taste receptor having more than one distinct subunit as the preferred T1R1 and T1R3 subunits of a umami receptor, one may fuse each subunit with a luminescent protein such as a luciferase protein or only one of the subunits. This holds for each taste receptor, i.e. the skilled person will understand that this also holds for other (hetero)multimeric taste receptors. If a taste receptor has more than one distinct subunit, each subunit may have been fused to a luminescent protein such as a luciferase protein. Alternatively, only one or more type of subunit will have been fused to a luminescent protein such as a luciferase.
In the invention, a fluorescent protein is fused to a β-arrestin. A preferred fluorescent protein is a green fluorescent protein (GFP). More preferred is GFP2.
A preferred β-arrestin is a human or mammalian β-arrestin. More preferably the β-arrestin is a non-visual β-arrestin such as e.g. β-arrestin 2 or 3. Most preferably the β-arrestin is a β-arrestin 2 which is represented by SEQ ID NO:79. A preferred nucleic acid molecule encoding said β-arrestin 2 is represented by SEQ ID NO:80. An even more preferred β-arrestin 2 has been described in WO2004/065963 or in WO 2004/034054. The fusion between a fluorescent protein and a β-arrestin is also known to the skilled person. In a method of the invention, each nucleic acid molecule (i.e. the one encoding a taste receptor fused to a luciferase and the one encoding a fluorescent protein fused to a β-arrestin) is present in a nucleic acid construct. Each construct is introduced into a cell.
A cell of the invention therefore comprises a nucleic acid construct as defined herein. The skilled person will know that the choice of the cell depends largely on the origin of the nucleic acid sequence encoding the taste receptor. Any cell can be chosen as long as a taste receptor as expressed is functional. Preferably, the expression of a taste receptor and/or of a β-arrestin is stable, optionally inducible. Alternatively, the expression of a taste receptor and/or of a β-arrestin is transient. Inducible expression is extensively explained in the section “expression of a taste receptor”. Preferably, a cell is a prokaryote or an eukaryote cell. More preferably, the cell is an insect or a mammalian cell. Even more preferably, the mammalian cell is a human cell. Examples of mammalian cells are HEK293, HEK293T, MDCK, CHO, COS, NIH3T3, Swiss3T3, BHK, and A549. Even more preferably, a cell is a mammalian cell such as HEK293. A cell of the invention may be seen as a recombinant cell. A cell of the invention is advantageously used in a method of the invention.
Depending on the type of expression system chosen, the skilled person may possibly adapt the culture conditions to obtain a most favorable expression level of a taste receptor and of a β-arrestin. In the case of an inducible expression system, the skilled person may also possibly optimize an inducing condition. The time period of induction of the expression and the temperature during induction of the expression could also possibly be optimized. According to a preferred embodiment, at the onset of the induction of expression of a taste receptor, sub-confluent cells are placed in a 96 well plate with a suitable culture medium. Sub-confluent preferably means 70% confluent, more preferably 80% confluent. In a preferred embodiment, the inducing agent added is tetracycline or doxycyclin when using an inducible expression system, preferably a tetracyclin-regulated promoter.
In an embodiment, cells may be transiently transfected with a nucleic acid molecule encoding a taste receptor fused to a luminescent protein such as a luciferase protein and a nucleic acid molecule encoding a fluorescent protein fused to a β-arrestin. If a taste receptor has more than one distinct subunit, one may use one nucleic acid molecule per subunit. Alternatively one may use one single nucleic acid molecule comprising more than one type of subunit. Transient transfection may be carried out using Lipofectamine 2000 according to the manufacturers' protocol. Briefly, cells may be seeded at a density of 2×105 cells per well (12-wells plate, 1 ml medium/well), aiming at a confluency of about 80-90% the next day. After 24 h, a nucleic acid molecule encoding a taste receptor fused to a luminescent protein such as a luciferase may be co-transfected with a nucleic acid molecule encoding a fluorescent protein fused to a β-arrestin. A total of 15 μg of total DNA may be used per well. A mixture comprising said DNA may be incubated for 30 minutes at room temperature, added to each well and the cells allowed to grow for 48 hours. A BRET measurement may be carried out 48 h-52 h after transfection. Alternatively, a nucleic acid molecule encoding a taste receptor fused to a luminescent protein such as a luciferase protein may be transfected into cells stably expressing a fluorescent protein fused to a β-arrestin using the same protocol as described above. A preferred transfection protocol is described in the experimental part for HEK293 cells.
In a preferred embodiment, a taste receptor comprises a T1R1 and a T1R3 subunit and at least one of the subunits is fused to a luminescent protein such as a luciferase: T1R1 or T1R3 or both subunits. Preferably, a luciferase protein is a Renilla luciferase. A preferred nucleic acid sequence encoding a preferred T1R1 subunit fused to a Renilla luciferase is represented by SEQ ID NO:5. A corresponding preferred encoded amino acid sequence is represented by SEQ ID NO:6. A preferred nucleic acid sequence encoding a preferred T1R3 subunit fused to a Renilla luciferase is represented by SEQ ID NO:7. A corresponding preferred encoded amino acid sequence is represented by SEQ ID NO:8.
In a further preferred embodiment, a fluorescent protein fused to a β-arrestin is a GFP protein, preferably a GFP2 and β-arrestin is a β-arrestin 2.
Even more preferably, a taste receptor comprises a T1R1 and a T1R3 subunit and each subunit is fused to a luminescent protein such as a luciferase protein, preferably to a luciferase, more preferably to a Renilla luciferase and a fluorescent protein fused to a β-arrestin is a GFP protein, preferably a GFP2 and β-arrestin is a β-arrestin 2.
It is further encompassed by the present invention that a luminescent protein may be a luciferase protein. Alternatively, a luminescent protein may be another suitable energy donor. It is also encompassed by the present invention that a GFP may be replaced by another suitable energy acceptor. Theoretically any fluorescent protein or molecule defined as being a member of a structurally homologous class of proteins that can form a visible wavelength chromophore within its own polypeptide sequence could be used. Several fluorescent proteins have already been used in a BRET technology (see Bacart J. Et al, (2008) Biotechnol. J. 3:311-324 and Pfleger K. D., et al, (2006), Nature Methods, 3: 165-174).
A luminescent protein such as a luciferase and a GFP are herein presented as a preferred energy donor and energy acceptor respectively. Each of the features defined for a luminescent protein such as a luciferase or a GFP also holds for any other energy donor or energy acceptor respectively.
Therefore, in a method of the invention:
(a) at least one of the subunits of a taste receptor, preferably at least one of T1R1 and T1R3 is fused to a luminescent protein such as a luciferase protein or each subunit of a taste receptor, preferably T1R1 and T1R3 are each fused to a luminescent protein such as a luciferase protein
and/or
(b) a fluorescent protein fused to a β-arrestin is a GFP protein, preferably the GFP is a GFP2 and/or β-arrestin is a β-arrestin 2.
Alternatively, in a method of the invention:
(a) at least one of the subunits of a taste receptor, preferably at least one of T1R1 and T1R3 is fused to a fluorescent protein or each subunit of a taste receptor, preferably T1R1 and T1R3 are fused to a fluorescent protein
and/or
(b) a luminescent protein is fused to a β-arrestin.
Alternatively, in a method of the invention:
(a) the taste receptor is a T1R1, T1R3 heterodimer, wherein at least one of the subunits T1R1 and T1R3 is fused to a luminescent protein, and wherein a fluorescent protein is fused to a β-arrestin; or,
(b) the taste receptor is a T1R1, T1R3 heterodimer, wherein at least one of the subunits T1R1 and T1R3 is fused to a fluorescent protein, and wherein a luminescent protein is fused to a β-arrestin.
Preferably in a method of the invention at least one of: (a) the luminescent protein is a luciferase; (b) the fluorescent protein is a GFP; and, (c) the β-arrestin is a non-visual β-arrestin. More preferably, at least one of: (a) the luciferase is a Renilla luciferase; and, (b) the non-visual β-arrestin is a β-arrestin 2.
Step b) comprises challenging a cell as obtained in step a) with a potential modulator compound.
In this context, challenging may mean contacting a cell obtained in step a) with a potential modulator compound.
A potential modulator compound of a taste receptor is herein defined as a compound that can block, inhibit, modulate or enhance a taste perception by blocking, inhibiting, modulating or enhancing the capacity of a taste receptor to be activated and therefore to transduce an intracellular signal into a cell. Any molecule, e.g. any organic molecule, either naturally occurring or synthetic, e.g., protein, oligopeptide, small organic molecule, polysaccharide, lipid (e.g. sphingolipid), fatty acid, polynucleotide, oligonucleotide, etc can be tested in a method of the invention. The potential modulator compound can be in the form of a library of compounds, such as a combinatorial or randomized library that provides a sufficient range of diversity.
The potential modulator compound will usually be present in an aqueous sample solution. Such an aqueous sample solution can comprise at least one of (a) a food product; (b) an extract of a food product; and (c) an extract of biomass, preferably an extract of edible biomass. Thus, the sample solution may comprise a liquid food product or a dilution thereof. The liquid food product may e.g. be a beverage or sauce like e.g. a soy sauce. The aqueous sample solution may also comprise an extract of a food product e.g. an extract of a solid food product (e.g. cheese) or a fat food product. Or the aqueous sample solution may comprise an extract of biomass from at least one of a plant, an animal and a microorganism. Thus, the aqueous sample solution may be an comprising soluble molecules from at least one of a plant, an animal and a microorganism. The aqueous sample solution may thus comprise an extract from a fermented food product. In a preferred embodiment the sample solution comprises a tomato extract. The extracts are further as defined herein below and may be prepared as defined herein below.
A advantage of the method of the invention is that it allows identification of potential modulators in complex samples. Thus preferably the aqueous sample solution is a complex sample solution. The aqueous sample solution can be a mixture comprising at least two distinct organic molecules, preferably comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more than 50 or more than 100. The number of compounds is preferably assessed as identified below. An aqueous sample solution may be defined as a complex sample solution when it comprises more than 10 distinct organic molecules, preferably more than 10 distinct potential modulators. It is further understood that the aqueous sample solution will usually be a solution of undefined composition, as opposed to e.g. reference solution comprising a predetermined amount of one or more defined modulators. Thus a solution of undefined composition is a solution comprising compounds whose identity and/or concentration is not known or defined.
The aqueous sample solution preferably is a solution comprising only solubles. Insolubles may be removed from the sample solution by means known in the art and described herein below for extracts. The aqueous sample solution further can be adjusted to be physiologically compatible with the cells provide in step a) by adjusting the solution to a physiologically acceptable pH and osmotic value.
In a preferred embodiment, such a modulator is present in an extract. An extract is a mixture comprising at least two distinct molecules, at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more than 50 or more than 100. The number of compounds is preferably assessed as identified below. An extract may be defined as a complex extract when it comprises more than 10 distinct molecules. An extract is a mixture comprising at least two distinct organic molecules, at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more than 50 or more than 100. The number of compounds is preferably assessed as identified below. An extract may be defined as a complex extract when it comprises more than 10 distinct organic molecules. An extract may not be purified and may be a plant-based extract, preferably a tomato extract or an animal-based extract and/or a food-based extract. An extract may be a food-based or food-derived extract. A food-based or food-derived extract may be seen as a food composition or a food product or as based on or derived from a food composition or food product. The identity of the extract, its composition and the way an extract has been prepared is not important for the invention. On the contrary, the advantages of the invention is that potentially from each extract, one may identify a potential modulator of a taste receptor using a method of the invention.
An extract may be a not-purified mixture obtained by using a solvent (e.g. water) or a solvent mix (e.g. water/alcohol) for extraction of plant, animal and/or microbial biomass, e.g. fresh, processed, fermented and/or dried plant or animal or food material containing all the soluble compounds from said material, preferably in a similar ratio as present in the original material and preferably corrected according to their solubility.
The number and concentration of compounds in an extract may be assessed knowing their presence in the original plant or animal or food material, their solubility in the solvent system used and known techniques to the skilled person such as using chromatography (HPLC, GC) and/or spectroscopic technique (NMR, Mass).
The preparation of extracts to be used in the invention usually involves at least two steps: 1) a solubilisation and/or homogenisation step; and 2) a step wherein insolubles, and optionally non-aqueous phases or solvents, are removed. A possible way of producing a suitable extract may be the treatment of a plant or animal or food material, which can be pre-processed (e.g. by cutting, macerating, drying, powdering etc.) by a suitable solvent (e.g. water, alcohol) or solvent mix (e.g. water/alcohol) under usual process conditions (e.g. heating, stirring, grinding,) and downstream processed (e.g. filtration, centrifugation, drying).
In a preferred method, a known activator of a taste receptor is further added in step b). Preferred known activators of a taste receptor have already been identified in table 1. An activator may be used in the search for an inhibitor: a taste receptor is first contacted with an activator to generate a BRET signal (i.e. a higher signal than the basal activity of said receptor). Subsequently, a potential inhibitor compound is contacted together with said activator. If a generated signal is reduced, said potential inhibitor compound is an inhibitor. An activator is preferably used in this context to increase the level of receptor activation which will then be lowered by the inhibitor; this increases the readout window and thereby the sensitivity.
Step c) comprises comparing a BRET signal of the cell obtained in step b) with a BRET signal of the cell obtained in b) in the absence of a potential modulator compound. Alternatively, step c) comprises comparing the BRET signal obtained in step b) with a BRET signal obtained from the cell in the absence of the potential modulator compound, wherein a difference between the BRET signal as obtained in b) and the BRET signal obtained in the absence of the potential modulator compound, is indicative of the potential modulator compound being a compound which modulates a taste receptor.
A BRET technique or assay leading to the generation of a BRET signal may be any BRET technique known to the skilled person. Any known variant of a luminescent donor luminescent protein such as a luciferase protein which is fused to a taste receptor may be used. The same holds for a luminescent acceptor also called fluorophore or fluorescent protein or energy acceptor protein such as a β-arrestin fused to a fluorescent protein. Depending on the identity of the luminescent donor and the luminescent acceptor, one will use a BRET 1 or BRET2 or BRET3 technique. The identity of proteins, conditions and wave lengths used for several BRET assays are known to the skilled person, see for example in Bacart J. et al (2008), Biotechnol. J. 3: 311-324. However, each of the proteins used in a BRET technique may be modified to improve their spectrum properties, making them more suitable to a BRET technique. Preferably a BRET2 technique is used since it is expected to provide a better sensitivity and efficiency: better separation of the involved wavelength leading to an easier detection of a BRET signal.
Upon receptor stimulation with a potential modulator compound preferably present in an extract, a β-arrestin protein fused to a fluorescent protein interacts with the activated taste receptor thus bringing a fluorescent protein in close proximity with a luminescent protein such as a luciferase fused to said activated taste receptor, making energy transfer between these two proteins possible and generating a BRET signal. In the case of BRET2, the assay is preferably as follows: in the presence of oxygen, a luciferase catalyses the transformation of the substrate DeepBlueC into coelenteramide, which can be measured at 395-410 nm. If a fluorescent protein is in close proximity to a luminescent protein such as a luciferase and energy transfer takes place, the emission will shift to 510 nm; this is referred to as a BRET signal and is expressed as a ratio between the acceptor (a fluorescent protein) and the donor (a luminescent protein such as a luciferase). A BRET signal is herein defined as a detectable BRET signal: a ratio which is higher than 0. In order to ensure that a BRET signal is exclusively caused by a specific activation of a taste receptor, we preferably compare a BRET signal obtained with cells expressing a taste receptor fused to a luminescent protein such as a luciferase protein and a fluorescent protein fused to a β-arrestin to a BRET signal obtained with cells not expressing said receptor and/or with cells not expressing a taste receptor fused to a luminescent protein such as a luciferase protein and/or with cells not expressing a fluorescent protein fused to a β-arrestin. The skilled person knows how to carry out a BRET assay. Fluorescence is typically measured on a fluorescence plate reader. In one embodiment, we may use a Mithras LB 940 plate reader (Berthold Technologies). The protocol we may use is essentially the same as described by Packard BioOne or published protocols13 with slight modifications: cells may be transfected as described earlier herein. 48 h after transfection cells may be harvested and taken up in a BRET buffer (D-PBS containing 2 μg/ml Aprotinin) at a density of 2×106 cells/ml. After leaving the cells for 1 hour at room temperature for equilibration, 30 μl containing approximately 1×105 cells may be transferred to each well of a white 96 well plate. 10 μl of a potential modulating compound or extract (or buffer) and 10 μl of the substrate coelenterazine (final concentration 5 μM) may be added simultaneously to the cells using the injectors.
Immediately after the final injections, repeated sequential readings will be taken at the specific emission wavelength of the donor and the specific emission wavelength of the acceptor, taking the substrate used for generating the luminescent signal into account. A BRET signal may be determined as the ratio between the light signal measured for an acceptor protein and the light signal measured for a donor protein.
If the BRET technique is a BRET1 technique, the donor is Renilla luciferase [Rluc] and coelenterazine h as substrate; the acceptor is enhanced yellow fluorescent protein [enhanced YFP], YFP topaz, YFP citrine, YFP venus, YPet.).
Immediately after the final injections, repeated sequential readings will be taken a wavelength covering the peak of the specific emission wavelength of the Rluc/coleneterazine h (480 nm) and the peak of the specific emission wavelength of the acceptor (530 nm). A BRET signal may be determined as the ratio between the light signal measured for an acceptor protein and the light signal measured for the donor protein.
If the technique is a BRET2 technique, the donor is Renilla luciferase [Rluc] or Renilla luciferase mutant 8 [Rluc8] (Loening A M, et al, Protein Eng Des Sel 2006 September; 19(9):391-400 and Bacart J, et al, Biotechnol J 2008 March; 3(3):311-24.) and DeepBlueCTM or coelenterazine 400a as substrate; the acceptor is Green fluorescent protein-2 [GFP2] or green fluorescent protein 10 [GFP10]).
Immediately after the final injections, repeated sequential readings will be taken at a wavelength covering the peak of the specific emission wavelength of the Rluc/coleneterazine 400a (395 nm) and the peak of the specific emission wavelength of the acceptor (510 nm). A BRET signal may be determined as the ratio between the light signal measured for an acceptor protein and the light signal measured for the donor protein.
A BRET signal of a cell obtained in step c) is compared with corresponding absence of a BRET signal of a cell obtained in c) in the absence of a potential modulator compound. Alternatively, a change in a BRET signal of a cell obtained in step c) is compared with a corresponding original BRET signal of a cell obtained in c) in the absence of a potential modulator compound.
Alternatively, the BRET signal obtained in step b) is compared with the background (or absence of a) BRET signal obtained from the cell in the absence of the potential modulator compound. A difference between the BRET signal as obtained in b) and the BRET signal obtained in the absence of the potential modulator compound, is indicative of the potential modulator compound being a compound which modulates a taste receptor. Alternatively, the BRET signal obtained in step b) may compared with a corresponding original BRET signal of a cell obtained in step b) in the absence of a potential modulator compound. A difference between the BRET signal as obtained in b) and the BRET signal obtained in the absence of the potential modulator compound, is indicative of the potential modulator compound being a compound which modulates a taste receptor. Likewise, the BRET signals obtained with two or more different sample solution may be compared whereby the different sample solution may contain different fractions of a food products, extracts of a food product, and/or extracts of biomass as described above.
A compound that increases a BRET signal or that induces a detectable BRET signal is a potential enhancer of a taste. In contrast, a compound that decreases a BRET signal is a potential masker of a taste.
According to a preferred embodiment, a potential enhancer of a taste has been identified when the comparison performed in step c) indicates the presence of a BRET signal or a detectable BRET signal or a detectable increase of a BRET signal of at least 2%. More preferably, a potential enhancer of a taste has been identified when the comparison performed in step c) indicates an increase of at least 4%, of at least 6%, of at least 8%, of at least 10%, of at least 12%, of at least 14%, of at least 16%, of at least 18%, of at least 20%, of at least 22%, of at least 24%, of at least 26%, of at least 28%, of at least 30%, of at least 32%, of at least 34%, of at least 36%, of at least 38%, of at least 40%, of at least 42% or more, of a BRET signal.
According to another preferred embodiment, a potential masker of a taste has been identified when the comparison performed in step c) indicates a decrease of at least 2% of a BRET signal. More preferably, a potential masker of a taste has been identified when the comparison performed in step c) indicates a decrease of at least 4%, of at least 6%, of at least 8%, of at least 10%, of at least 12%, of at least 14%, of at least 16%, of at least 18%, of at least 20%, of at least 22%, of at least 24%, of at least 26%, of at least 28%, of at least 30%, of at least 32%, of at least 34%, of at least 36%, of at least 38%, of at least 40%, of at least 42% or more of a BRET signal.
If a known inhibitor or activator of a taste receptor is present, the increase or decrease respectively of a BRET signal is compared to the BRET signal obtained in the absence of said potential modulator compound.
In a further aspect, there is provided a potential modulator compound of a taste receptor identified by a method as identified herein.
In another aspect, the invention pertains to a method for producing a compound which modulates a taste receptor. The method comprises the steps of identifying the compound which modulates a taste receptor in a method as defined herein, and recovery of the compound. Methods for recovering and/or (partial) purification of compound modulating taste are known to the skilled person per se.
In yet another aspect, the invention pertains to the use of a BRET technique or assay for identification of a compound which modulates a taste receptor. The BRET technique or assay may be used in accordance with the methods of the invention described herein.
General Technical Information
Nucleic Acid Molecule Defined by a SEQ ID NO and Sequence Identity
It is to be understood that each gene or nucleic acid molecule as identified herein by a given Sequence Identity Number (for example SEQ ID NO 1) is not limited to this specific sequence as disclosed. Each gene sequence or nucleotide sequence as identified herein encodes a given protein or polypeptide as identified herein. Throughout this application, each time one refers to a specific nucleotide sequence SEQ ID NO (take SEQ ID NO:1 as example), one may replace it by:
i. a nucleotide sequence comprising a nucleotide sequence that has at least 60% sequence identity with SEQ ID NO:1,
ii. a nucleotide sequences the complementary strand of which hybridizes to a nucleic acid molecule of sequence of (i) or (ii);
iii. a nucleotide sequence the sequence of which differs from the sequence of a nucleic acid molecule of (i) due to the degeneracy of the genetic code.
iv. a nucleotide sequence that encodes an amino acid sequence that has at least 60% amino acid identity with an amino acid sequence encoded by a nucleotide sequence SEQ ID NO:1.
Each nucleotide sequence or amino acid sequence described herein by virtue of its identity percentage (at least 60%) with a given nucleotide sequence or amino acid sequence respectively has in a further preferred embodiment an identity of at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or more identity with the given nucleotide or amino acid sequence respectively. In a preferred embodiment, sequence identity is determined by comparing the whole length of the sequences as identified herein.
“Sequence identity” is herein defined as a relationship between two or more amino acid (polypeptide or protein) sequences or two or more nucleic acid (polynucleotide) sequences, as determined by comparing the sequences. In the art, “identity” also means the degree of sequence relatedness between amino acid or nucleic acid sequences, as the case may be, as determined by the match between strings of such sequences. “Similarity” between two amino acid sequences is determined by comparing the amino acid sequence and its conserved amino acid substitutes of one polypeptide to the sequence of a second polypeptide. “Identity” and “similarity” can be readily calculated by known methods, including but not limited to those described in (Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heine, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., SIAM J. Applied Math., 48:1073 (1988).
Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include e.g. the GCG program package (Devereux, J., et al., Nucleic Acids Research 12 (1): 387 (1984)), BestFit, BLASTP, BLASTN, and FASTA (Altschul, S. F. et al., J. Mol. Biol. 215:403-410 (1990). The BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S., et al., NCBI NLM NIH Bethesda, Md. 20894; Altschul, S., et al., J. Mol. Biol. 215:403-410 (1990). The well-known Smith Waterman algorithm may also be used to determine identity.
Preferred parameters for polypeptide sequence comparison include the following: Algorithm: Needleman and Wunsch, J. Mol. Biol. 48:443-453 (1970); Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff, Proc. Natl. Acad. Sci. USA. 89:10915-10919 (1992); Gap Penalty: 12; and Gap Length Penalty: 4. A program useful with these parameters is publicly available as the “Ogap” program from Genetics Computer Group, located in Madison, Wis. The aforementioned parameters are the default parameters for amino acid comparisons (along with no penalty for end gaps).
Preferred parameters for nucleic acid comparison include the following: Algorithm: Needleman and Wunsch, J. Mol. Biol. 48:443-453 (1970); Comparison matrix: matches=+10, mismatch=0; Gap Penalty: 50; Gap Length Penalty: 3. Available as the Gap program from Genetics Computer Group, located in Madison, Wis. Given above are the default parameters for nucleic acid comparisons.
Optionally, in determining the degree of amino acid similarity, the skilled person may also take into account so-called “conservative” amino acid substitutions, as will be clear to the skilled person. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulphur-containing side chains is cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine. Substitutional variants of the amino acid sequence disclosed herein are those in which at least one residue in the disclosed sequences has been removed and a different residue inserted in its place. Preferably, the amino acid change is conservative. Preferred conservative substitutions for each of the naturally occurring amino acids are as follows: Ala to ser; Arg to lys; Asn to gln or his; Asp to glu; Cys to ser or ala; Gln to asn; Glu to asp; Gly to pro; His to asn or gln; Ile to leu or val; Leu to ile or val; Lys to arg; gln or glu; Met to leu or ile; Phe to met, leu or tyr; Ser to thr; Thr to ser; Trp to tyr; Tyr to trp or phe; and, Val to ile or leu.
Expression of a Taste Receptor in a Cell
A taste receptor and a β-arrestin for use in a method of the present invention can be prepared using recombinant techniques, in which a nucleotide sequence encoding a taste receptor fused to a luciferase protein and another one encoding a β-arrestin fused to a fluorescent protein are expressed in a suitable cell. The present invention thus also concerns the use of a vector comprising said nucleic acid molecule represented by said nucleotide sequence as defined above. Preferably a vector is a replicative vector comprising an origin of replication (or autonomously replication sequence) that ensures multiplication of a vector in a suitable host for the vector. Alternatively a vector is capable of integrating into a cell's genome, e.g. through homologous recombination or otherwise. A particularly preferred vector is an expression vector wherein a nucleotide sequence encoding a polypeptide as defined above, is operably linked to a promoter capable of directing expression of a coding sequence in a cell for the vector.
As used herein, the term “promoter” refers to a nucleic acid fragment that functions to control the transcription of one or more genes, located upstream with respect to the direction of transcription of the transcription initiation site of the gene, and is structurally identified by the presence of a binding site for DNA-dependent RNA polymerase, transcription initiation sites and any other DNA sequences, including, but not limited to transcription factor binding sites, repressor and activator protein binding sites, and any other sequences of nucleotides known to one skilled in the art to act directly or indirectly to regulate the amount of transcription from the promoter. A “constitutive” promoter is a promoter that is active under most physiological and developmental conditions. An “inducible” promoter is a promoter that is regulated depending on physiological or developmental conditions. An expression vector allows a polypeptide as defined above to be prepared using recombinant techniques in which a nucleotide sequence encoding said polypeptide is expressed in a suitable cell, e.g. cultured cells.
Preferably the expression of each of the nucleic acid sequence of the invention defined above is inducible. The inducibility of the expression of each nucleic acid sequence can be fulfilled by any way known to the skilled person. For example, the Invitrogen T-Rex system (Tetracycline-Regulated Expression, based on the tet operon, expression of the inserted gene is repressed until an inducer is added to the media), the Invitrogen Gene-Switch System (based on activation of the GaW-EIb promoter), the Stratagene Complete Control Inducible mammalian Expression system (based on transcription activation by the insect hormone ecdysone or its analog ponasterone A (ponA) in mammalian cells harboring both the gene for the Drosophila melanogaster ecdysone receptor and a promoter containing a binding site for the ecdysone receptor), the New England Biolabs RheoSwitch® Mammalian Inducible Expression System (based on the highly specific interaction of a synthetic inducer, RheoSwitch Ligand RSLI, and a chimeric bipartite nuclear receptor), the Qbiogene Q-mateTM Inducible Expression System, or Q-mateTM CymR system (based on repression of gene expression by the cumate repressor protein CymR bound to operator sites in the absence of the inducer molecule cumate. With cumate present, CymR binds to cumate and undergoes a conformational change resulting in its release from the operator sites.), the Stratagene's LacSwitch® II inducible mammalian expression system (based on the lac operon, expression of the inserted gene is repressed until an inducer is added to the media). Even more preferably, the expression of each nucleic acid sequence is rendered inducible by the presence of an inducible promoter operably linked to each of the nucleic acid subsequence present in the nucleic acid sequence of the invention. In the context of the invention, “operably linked” is defined as a configuration in which a control sequence, here a promoter sequence, is appropriately placed at a position relative to the nucleic acid subsequence such that the control sequence directs the expression of the nucleic acid subsequence.
An inducible promoter may be any promoter or parts thereof functional for a given nucleic acid subsequence as defined above and in a given cell, wherein the transcription initiation activity of the promoter can be induced in a cell upon the addition of a given inducing agent during culture of the cells. More preferably, the inducible promoter is a tetracycline-regulated promoter. Even more preferably, the inducible promoter is a tetracyclin-regulated hybrid human cytomegalovirus promoter as described in Yao et al (Yao, F. et al. (1998) Hum. Gene Therapy 9: 1939-1950 and Yao, F. and Eriksson, E. (1999) Hum. Gene Therapy 10: 419-427). This system can be purchased from Invitrogen as the T-Rex expression system). The use of an inducible expression system may circumvent the toxicity problem described using a stable expression system.
Typically, a nucleic acid encoding a polypeptide as defined above is used in an expression vector. The phrase “expression vector” generally refers to a nucleotide sequence that is capable of effecting expression of a gene in a host compatible with such sequences. These expression vectors typically include at least a suitable promoter sequence and optionally, a transcription termination signal. Additional factors necessary or helpful in effecting expression can also be used as described herein. A nucleic acid or DNA encoding a polypeptide is incorporated into a DNA construct capable of introduction into and expression in an in vitro cell culture. Specifically, a DNA construct is suitable for replication in a prokaryotic host, such as bacteria, e.g., E. coli, or can be introduced into a cultured mammalian, plant, insect, e.g., Sf9, yeast, fungi or another eukaryotic cell line.
A DNA construct prepared for introduction into a particular cell typically includes a replication system recognized by the host, the intended DNA segment encoding a desired polypeptide, and transcriptional and translational initiation and termination regulatory sequences operably linked to a polypeptide-encoding segment. A DNA segment is “operably linked” when it is placed into a functional relationship with another DNA segment. For example, a promoter or enhancer is operably linked to a coding sequence if it stimulates the transcription of the sequence. However, an enhancer need not be contiguous with a coding sequence whose transcription it controls. Linking is accomplished by ligation at convenient restriction sites or at adapters or linkers inserted in lieu thereof.
The selection of an appropriate promoter sequence generally depends upon the cell type selected for the expression of a DNA segment. Examples of suitable promoter sequences include prokaryotic and eukaryotic promoters well known in the art (see, e.g. Sambrook and Russell, 2001, supra). A transcriptional regulatory sequence typically includes a heterologous enhancer or promoter that is recognised by the host. The selection of an appropriate promoter depends upon the cell, but promoters such as the trp, lac and phage promoters, tRNA promoters and glycolytic enzyme promoters are known and available (see, e.g. Sambrook and Russell, 2001, supra). An expression vector including the replication system and transcriptional and translational regulatory sequences together with the insertion site for a polypeptide encoding segment can be employed. Examples of workable combinations of cell lines and expression vectors are described in Sambrook and Russell (2001, supra) and in Metzger et al. (1988) Nature 334: 31-36. For example, a suitable expression vector can be expressed in, yeast, e.g. S. cerevisiae, e.g., insect cells, e.g., Sf9 cells, mammalian cells, e.g., CHO cells and bacterial cells, e.g., E. coli. A cell may thus be a prokaryotic or eukarotic host cell. A cell may be a cell that is suitable for culture in liquid or on solid media. A cell is preferably used in a method of the invention as defined above.
In this document and in its claims, the verb “to comprise” and its conjugations is used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded. In addition the verb “to consist” may be replaced by “to consist essentially of” meaning that a method as defined herein may comprise additional step(s) than the ones specifically identified, said additional step(s) not altering the unique characteristic of the invention. In addition, reference to an element by the indefinite article “a” or “an” does not exclude the possibility that more than one of the elements is present, unless the context clearly requires that there be one and only one of the elements. The indefinite article “a” or “an” thus usually means “at least one”.
All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.
The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.



DESCRIPTION OF THE FIGURES
FIG. 1 Activation of the T1R1/T1R3 umami receptor expressed in HEK293-Gα15 cells as measured by monitoring the release of intracellular calcium using the calcium fluorescent marker Fluo-4-AM as described in Example 2. Activity of the umami receptor was measured as the change in fluorescence which was calculated by subtracting the maximum fluorescence after the addition of the test solution from the baseline fluorescence measured before addition of the test solution. Test solutions comprise extracts as indicated and prepared as described in Example 2. MSG=10 mM; MSG+IMP=1 mM MSG+500 μM IMP.
FIG. 2 Activation of the T1R1/T1R3 umami receptor expressed in HEK293-Gα15 cells as measured by BRET assays as described in Example 2. Test solutions (or buffer) as indicated and substrate were added to the cells. The BRET signals were determined as the ratio between readings taken at the acceptor wavelength (515 nm) divided by the signals determined for the donor (400 nm). To correct for background signal due to overlap of donor emission at the acceptor wavelength, the BRET ratio was determined in parallel for cells expressing the donor alone (T1R1/T1R3-Rluc). This BRET background value was subtracted from the BRET value obtained for the cells expressing both BRET partners (BRET=BRET ratio−background ratio). A BRET signal above the values achieved for buffer alone was defined as umami receptor-specific (see also table 2B).



EXAMPLES
Example 1
Proof of Principle Using the Human Umami Receptor T1R1/T1R3
We developed a unique functional umami receptor assay to evaluate and quantify umami in tomato and other crude plant or food extracts using the BRET technique: to test the principle we used the donor and acceptor proteins relating to BRET-2. In short, the human T1R1 and T1R3 taste receptors were cloned and fused with Renilla luciferase (Rluc) as donor protein; green fluorescent protein-2 (GFP2) served as acceptor protein and was fused to β-arrestin-2. Both constructs were transfected into a HEK293 cell line cells) for heterologous expression of the proteins. Various mammalian cell lines have been reported to be highly suitable for expression of receptors or other proteins, with HEK293 (human embryonic kidney) cells and CHO (Chinese hamster ovary) cells being some of the most versatile and suitable ones12. Similarly, GPCRs can be expressed in various ways as described in multiple publications, such as transient6, 8, 13-15 or stable (constitutive or inducible)6, 9, 16, 17 expression, depending on the nature of the experiment, the respective receptor or the available time.

Upon receptor stimulation with an agonist or crude extracts, the β-arrestin-2/GFP-2 protein interacts with the activated receptor thus bringing GFP-2 in close proximity with luciferase, making energy transfer between these two proteins possible and generating a BRET signal. In the presence of oxygen the luciferase catalyses the transformation of the substrate DeepBlueC into coelenteramide, which can be measured at 395-410 nm. If GFP-2 is in close proximity to the luciferase and energy transfer takes place, the emission will shift to 510 nm; this is referred to as the BRET signal and is expressed as ratio between the acceptor (GFP-2) and the donor (Renilla luciferase).

The following experiments are designed to illustrate that conventional calcium-based functional receptor assays are not suitable for measuring the effects of crude extracts; in contrast, the BRET assay (as indicated here with umami) can clearly measure specific receptor responses using crude natural extracts. Moreover, the assay is also sensitive enough for detecting differences of receptor activation between the different tomato samples.

Materials & Methods:

Chemicals and Media:

Fluo-4 AM was from Molecular Probes (# F-14202, prepared as 5 mM stock in DMSO), DMEM (with 4.5 g/l glucose and ultraglutamine, # BE12-604F) was from Lonza, trypsin-EDTA, Lipofectamine 2000, OptiMem and FCS were obtained from Life Technologies Invitrogen. Monosodium glutamate (MSG), Inosine 5′-monophosphate as well as all other chemicals were from Sigma-Aldrich. The plasmid encoding GFP2-β-arrestin-2 was purchased from BioSignal Packard (#6310176).

Coelenterazine 400A (a DeepBlueC derivative) and Coelenterazine-H were from VWR International (# BTIU10125-1 and 233903-50, respectively).

All other cell culture supplies were from Greiner BioOne.

Receptor Fusion Constructs, Cell Lines, and Media:

The human T1R1 and human T1R3 umami receptors were fused at their C-terminal in frame to Renilla Luciferase (Rluc) using standard molecular cloning techniques and the codon-humanized pRluc-N3 vector from PerkinElmer (#6310220). For expression of the umami receptors and the construct encoding GFP-2/β-arrestin-2, HEK293 cells (human embryonic kidney cells, ATCC) were used using traditional transfection methods (see also below).

HEK293 cells were maintained in DMEM and 10% FBS at 37° C./5% CO2.

Tomato Extracts:

The tomato extracts which served as representative natural, complex test material were prepared as follows: Frozen tomato samples (in −80° C.) were weighed and dissolved in an equal amount of water. After the seeds and locular tissues (pulp) were removed and put aside, the tomato pericarp (flesh) was ground using a mortar and pestle. The seeds and pulp were then added back to the mixture ensuring that they are well mixed and the seeds were not crushed. The mixture was centrifuged for 15 minutes at 4000 rpm, the supernatant (serum) removed and freeze-dried in 10 ml aliquots. Before the measurements, an equal volume of water was added to dissolve the sample.

Generation of the T1R1/T1R3 and Rluc Fusion Constructs:

As mentioned above, we have generated the C-terminal Rluc receptor fusion constructs of the human T1R1 and human T1R3 umami receptor using standard molecular cloning techniques. This resulted in 2 different constructs: T1R1-Rluc and T1R3-Rluc. They can be either transfected together, resulting in a functional receptor heterodimer containing two Rluc moieties; alternatively either construct can be transfected in combination with the wild type receptor, thus resulting in T1R1-Rluc combined with T1R3 or T1R1 combined with T1R3-Rluc.

The sequences (cDNA and protein) for the wild type receptors as well as the fusion constructs and the Renilla luciferase are given in the sequence listing (SEQ ID NO:5-8).

Transfections:

HEK293 cells will be transiently transfected with the plasmids encoding the T1R1/T1R3 receptors (containing the Rluc-fusion protein) as well the GFP-2-β-arrestin-2 using Lipofectamine 2000 according to the manufacturers' protocol. In short, HEK293 cells will be seeded at a density of 2×105 cells per well (12-wells plate, 1 ml medium/well), aiming at a confluency of about 80-90% the next day. After 24 h the umami receptor constructs (T1R1-Rluc, T1R3-Rluc, or wild type receptors) will be co-transfected with the plasmid encoding GFP-2-β-arrestin-2 using 15 μg of total DNA per well. We will dissolve the DNA in 100 μl of OptiMem and combine it with 100 μl of OptiMem containing 4 μl of lipofectamine 2000. The mixture will then be incubated for 30 minutes at room temperature, added to each well and the cells allowed to grow for 48 hours. BRET measurements will be carried out 48 h-52 h after transfection. Alternatively, the plasmids encoding the umami receptors can be transfected into HEK293 cells stably expressing the GFP-2-β-arrestin-2 using the same protocol as described above.

For the calcium-based receptor assay, HEK293 cells stably expressing Gα15 are transfected with the T1R1 and T1R3 receptors according to the procedure described above, but scaling down the protocol for 96 well plate format (10-fold reduction using a poly-Lysine coated μClear 96-wells plate).

Calcium-Based Receptor Assay:

Activation of the T1R1/T1R3 umami receptor expressed in HEK293-Gα15 cells has been measured by monitoring the release of intracellular calcium. The growth medium was removed and the cells were loaded for 1 hour with 50 μl Tyrode's buffer (140 mM NaCl, 5 mM KCl, 10 mM glucose, 1 mM CaCl2. 2 H2O, 1 mM MgCl2. 6 H2O, 10 mM Na-pyruvate and 50 mM HEPES pH 7.4) containing 2.5 μM of the fluorescent marker of calcium, Fluo-4-AM, supplemented with 0.5 mM probenicide to prevent leakage of Fluo-4 from the cells and 0.5% FCS, followed by a 1-hr incubation at 37° C. The mixture was removed, and 150 μl of Tyrode's buffer containing 0.5 mM probenicide was added. Intracellular calcium levels were monitored using a Flexstation II 384 (Molecular Devices). Fluorescence measurements were carried out at 37° C. at an excitation wavelength of 485 nm and an emission wavelength of 520 nm. 50 μl of compounds or tomato extracts were added to the cells at a pipettor speed of 104 μl per sec after a baseline measurement of 20 s. Activity of the umami receptor was measured as the change in fluorescence (ΔF) which was calculated by subtracting the maximum fluorescence after the addition of the test solution from the baseline fluorescence measured before addition of the test solution.

The data indicated in table 2A show very clearly that using pure umami compounds results in umami receptor-specific responses (control cells not expressing the receptor give no increase); in contrast, using various tomato extracts results in high non-specific responses in the control cells, making it impossible to indentify signals indicating umami.

BRET Assay:

For the BRET assay we will use a Mithras LB 940 plate reader (Berthold Technologies). The protocol we will use is essentially the same as described by Packard BioOne or published protocols13 with slight modifications: HEK 293 cells will be transfected as described above. 48 h after transfection they will be harvested and taken up in BRET buffer (D-PBS containing 2 μg/ml Aprotinin) at a density of 2×106 cells/ml. After leaving the cells for 1 hour at room temperature for equilibration, 30 μl containing approximately 1×105 cells will be transferred to each well of a white 96 well plate. 10 μl of test compounds (or buffer) and 10 μl of the substrate coelenterazine (final concentration 5 μM) will be added simultaneously to the cells using the injectors. Immediately after the final injections, sequential readings will be taken at 410 nm and 515 nm. The BRET signals will be determined as the ratio between GFP-2 emission (515 nm) and Rluc/coelenterazine emission (410 nm).

Example 2
Detection of Taste Modulators in Complex Samples
Preparation and Selection of Test Samples (Extracts)
The extracts or crude mixtures described below are examples for natural samples unsuitable for testing with a calcium-based receptor assay due to their high non-specific background signal. They are from different origin and are selected to illustrate a wide range of potential test samples. The selected samples are also known to contain glutamate, ribotides or both and are therefore good candidates to examine in a BRET assay using the umami receptor T1R1/T1R3 as example.

    
    
        Tomato: The preparation of tomato extract is already been described in Example 1
        Yeast extract: Commercially available yeast extract enriched for 5′-ribotides (DSM, Maxarome Select yeast extract). The yeast extract was dissolved in water (10× weight of yeast extract).
        Soy sauce: commercially available soy sauce was used (Conimex ketjap manis).
        Chicken bouillon: A commercially available chicken bouillon cube (Knorr) was dissolved in hot water as indicated by the manufacturers. To remove particles from the test sample the bouillon was centrifuged at 5000 rpm for 10 minutes and the supernatant transferred to a fresh tube.
        Cheese extract: commercially available Roquefort cheese was weighed and dissolved in an equal amount of water and homogenized using a mortar and pestle. The mixture was centrifuged for 10 minutes at 5000 rpm to remove particles and the supernatant transferred to a fresh tube.

Experimental Procedures

Transfections:

HEK293 cells were transiently transfected with the plasmids encoding the T1R1 and T1R3 receptors (the T1R3 receptor contained the Rluc-fusion protein in this experiment) as well the GFP-2-β-arrestin-2 using Lipofectamine 2000 according to the manufacturers' protocol. In short, HEK293 cells will be seeded at a density of 2×105 cells per well (12-wells plate, 1 ml medium/well), aiming at a confluency of about 80-90% the next day. After 24 h the umami receptor constructs (T1R1 and T1R3-Rluc receptors) were co-transfected with the plasmid encoding GFP-2-β-arrestin-2 using 15 μg of total DNA per well. The DNA was dissolved in 100 μl of OptiMem and combined with 100 μl of OptiMem containing 4 μl of lipofectamine 2000. The mixture was incubated for 30 minutes at room temperature, added to each well and the cells allowed to grow for 48 hours. BRET measurements were carried out 48 h-52 h after transfection.

Alternatively, the plasmids encoding the umami receptors were transfected into HEK293 cells stably expressing the GFP-2-β-arrestin-2 using the same protocol as described above.

For the calcium-based receptor assay, HEK293 cells stably expressing Gα15 are transfected with the T1R1 and T1R3 receptors according to the procedure described above, but scaling down the protocol for 96 well plate format (10-fold reduction using a poly-Lysine coated pClear 96-wells plate).

Calcium-Based Receptor Assay:

Activation of the T1R1/T1R3 umami receptor expressed in HEK293-Gα15 cells has been measured by monitoring the release of intracellular calcium. The growth medium was removed and the cells were loaded for 1 hour with 50 μl Tyrode's buffer (140 mM NaCl, 5 mM KCl, 10 mM glucose, 1 mM CaCl2. 2 H2O, 1 mM MgCl2. 6 H2O, 10 mM Na-pyruvate and 50 mM HEPES pH 7.4) containing 2.5 μM of the fluorescent marker of calcium, Fluo-4-AM, supplemented with 0.5 mM probenicide to prevent leakage of Fluo-4 from the cells and 0.5% FCS, followed by a 1-hr incubation at 37° C. The mixture was removed, and 150 μl of Tyrode's buffer containing 0.5 mM probenicide was added. Intracellular calcium levels were monitored using a Flexstation II 384 (Molecular Devices). Fluorescence measurements were carried out at 37° C. at an excitation wavelength of 485 nm and an emission wavelength of 520 nm. 50 μl of compounds or extracts were added to the cells at a pipettor speed of 104 μl per sec after a baseline measurement of 20 s. Activity of the umami receptor was measured as the change in fluorescence (ΔF) which was calculated by subtracting the maximum fluorescence after the addition of the test solution from the baseline fluorescence measured before addition of the test solution.

Table 2B and FIG. 1 illustrate that using pure umami compounds (MSG and MSG+IMP) results in umami receptor-specific responses; in contrast, using various extracts and natural mixtures results in high non-specific responses in control cells not expressing the umami receptor as well, thereby making it impossible to calculate receptor-specific signals indicating umami.

BRET Assay:

For the BRET assay we used a Mithras LB 940 plate reader (Berthold Technologies). The assay protocol is essentially the same as described by Packard BioOne or other published protocols10, 13 with slight modifications: HEK 293 cells were transfected as described above. 40 h after transfection they were harvested and taken up in BRET buffer (D-PBS containing 1 g/l D-glucose and 2 μg/ml Aprotinin) at a density of 2×106 cells/ml. After leaving the cells for 1 hour at room temperature for equilibration, 30 μl containing 1×105 cells were transferred to each well of a white 96 well plate. 10 μl of test compounds (or buffer) and 10 μl of the substrate coelenterazine 400 (DeepBlueC, final concentration 5 μM) were added to the cells using the injectors. Immediately after the final injections, sequential readings were taken at 400 nm and 515 nm. Alternatively, compounds were added to the cells manually and were incubated for 5 minutes before injection of the substrate. The BRET signals were determined as the ratio between readings taken at the acceptor wavelength (GFP-2; 515 nm) divided by the signals determined for the donor (Rluc/coelenterazine 400; 400 nm). To correct for background signal due to overlap of donor emission at the acceptor wavelength, the BRET ratio was determined in parallel for cells expressing the donor alone (T1R1/T1R3-Rluc). This BRET background value was subtracted from the BRET value obtained for the cells expressing both BRET partners (BRET=BRET ratio−background ratio). A BRET signal above the values achieved for buffer alone was defined as umami receptor-specific (see table 2B).

Results:

As indicated in table 2B and FIG. 1, it was not possible to achieve umami receptor-specific signals using representative extracts and other complex mixtures using the calcium-based receptor assay. In contrast, FIG. 2 shows that using the described BRET assay it was possible to specifically measure umami receptor activation for these complex samples.

The definition of receptor-specific signals differs slightly for technical reasons: For the calcium assay, cells expressing the umami receptor and Gα15 are compared with cells expressing Gα15 only; the difference between these signals is defined as umami receptor-specific signal. For the BRET assay the background is determined using cells expressing the donor only (T1R1/T1R3-Rluc); a positive value indicates a specific BRET signal.

    
    









TABLE 1







non-exhaustive list of agonist of several taste receptors as identified








Receptor
agonist





T1R1/T1R3
MSG, (L-glutamate), positive allosteric



modulator: IMP (inosine monophosphate)


mGluR4
MSG, L-AP4 (L-(+)-2-Amino-4-



phosphonobutyric acid)


T1R2/T1R3
Sweeteners (natural and artificial): Glucose,



sucrose, saccharose


GPR120
Medium and long-chain fatty acids (linoleic acid)


GPR93
LPA (lysophosphatidic acid), proteolytic



degradation products


FFAR1
Medium and long-chain fatty acids



(eicosatrienoic acid, linoleic acid)


FFAR2
Short chain fatty acids (acetate, propionate)


FFAR3
Short chain fatty acids (acetate, propionate)


GPRC6A
L-amino acids (most potent L-arginine)


GPR84
Medium chain fatty acids (Capric acid,



Undecanoic acid)


TAS2R7
Quinacrine, chloroquine, papaverine, strychnine


TAS2R14
Picrotoxin, picrotoxinin, α-thujone, naphthoic



acid (8 in total)


TAS2R161
β-glucopyranosides (e.g. salicin, phenyl-β-D-



glucopyranoside)


TAS2R381
Phenylthiocarbamide, PROP, acetylthiourea



and others


TAS2R43
Saccharin, acesulfame K, aristolochic acid



6-Nitrosaccharin


TAS2R44
Saccharin, acesulfame K, aristolochic acid


TAS2R461
Sesquiterpenes



Absinthine, denatonium benzoate


TAS2R47
6-nitrosaccharin and saccharin


TAS2R4
Quinine, denatonium benzoate


TAS2R8
Ranitidine, denatonium benzoate


TAS2R10
Strychnine, brucine, denatonium benzoate,



absinthine


TAS2R39
Acetaminophen, ranitidine, denatonium



benzoate


TAS2R45
Absinthine


TAS2R48
Absinthine


T2R1/TAS2R1
chloroquine, dexamethasone, quinine


T2R3/TAS2R3
chloroquine, 2-acetylpyrazine


T2R4/TAS2R4
quinine, denatonium benzoate


T2R5/TAS2R5
dimethylbiguanide, oleuropein


T2R7/TAS2R7
quinacrine, chloroquine, papaverine,



strychnine


T2R8/TAS2R8
ranitidine, denatonium benzoate


T2R9/TAS2R9
ranitidine, ofloxacin


T2R10/TAS2R10
strychnine, brucine, denatonium benzoate,



absinthine


T2R13/TAS2R13
ethylpyrazine, quinacrine


T2R14/TAS2R14
picrotoxin, picrotoxinin, α-thujone, naphthoic



acid


T2R16/TAS2R16
β-glucopyranosides (e.g. salicin, phenyl-β-



D-glucopyranoside)


T2R24/TAS2R42
Not known


T2R44/TAS2R47
6-nitrosaccharin and saccharin


T2R50/TAS2R45
absinthine


T2R51/TAS2R38
phenylthiocarbamide, PROP, acetylthiourea


T2R54/TAS2R39
acetaminophen, ranitidine, denatonium



benzoate


T2R55/TAS2R40
linamarin, oxybutynin chloride


T2R61/TAS2R43
saccharin, acesulfame K, aristolochic acid



6-Nitrosaccharin


T2R63/TAS2R49
Not known


T2R64/TAS2R44
saccharin, acesulfame K, aristolochic acid


T2R65/TAS2R48
Absinthine, ethylpyrazine


T2R67/TAS2R50
ethylpyrazine, oxybutynin chloride


T2R71/TAS2R41
Nitrosaccharin


T2R75/TAS2R46
sesquiterpenes



absinthine, denatonium benzoate


T2R76
brucine
















TABLE 2A







Specific activation of a T1R1/T1R3 umami 


receptor measured by the


release of intracellular calcium: average values are shown










T1R1/T1R3
Control cells 



umami receptor
(no T1R1/T1R3)













Compounds
meas. 1
meas. 2
average
meas. 1
meas. 2
average

















100 
μM MSG
1146 
1193
1170
1102
1168
1135


1
mM MSG
2548 
3990
3269
1100 
1020
1060


10 
mM MSG
5766 
7732
6749
1200
1030
1115













extract 1
4649 
7985
6317
6420
3449
4934


extract 2
4552 
6461
5506
7435
6061
6748


extract 3
5980
5080
5530
4369
5431
4900


extract 4
5394 
4285
4839
5848
5784
5816


extract 5
6338 
9179
7759
6423
6318
6370


extract 6
9285 
10503
9894
10708
9785
10247
















TABLE 2B







T1R1/T1R3 receptor-specific signals using the calcium or BRET assay











Test samples
Calcium assay
BRET assay







MSG 10 mM
+
+



MSG 1 mM + IMP 500 μM
+
+



Tomato extract
−
+



Yeast extract
−
+



Chicken bouillon
−
+



Soy sauce
−
+



Cheese extract
−
+

















TABLE 3







SEQ ID NO of the DNA/amino acid sequences of taste


receptors identified in the sequence listing










SEQ ID NO




of human
SEQ ID NO of human


Taste receptor subunit
DNA sequence
amino acid sequence












T1R1
1
2


T1R3
3
4


T1R2
9
10


mGluR4a
11
12


GPR120
13
14


GPR93
15
16


FFA receptor 1
17
18


FFA receptor 2
19
20


FFA receptor 3
21
22


GPR84
23
24


mGluR4c
25
26


T2R1 (=TAS2R1)
27
28


T2R3 (=TAS2R3)
29
30


T2R4 (=TAS2R4)
31
32


T2R5 (=TAS2R5)
33
34


T2R7 (=TAS2R7)
35
36


T2R8 (=TAS2R8)
37
38


T2R9 (=TAS2R9)
39
40


T2R10 (=TAS2R10)
41
42


T2R13 (=TAS2R13)
43
44


T2R14 (=TAS2R14)
45
46


T2R16 (=TAS2R16)
47
48


T2R24 (=TAS2R42)
49
50


T2R44 (=TAS2R47)
51
52


T2R50 (=TAS2R45)
53
54


T2R51 (=TAS2R38 = T2R61)
55
56


T2R54 (=TAS2R39 = T2R57)
57
58


T2R55 (=TAS2R40 = T2R58)
59
60


T2R61 (=TAS2R43 = T2R52)
61
62


T2R63 (TAS2R49 = T2R56)
63
64


T2R64 (=TAS2R44 = T2R53)
65
66


T2R65 (=TAS2R48 = T2R55)
67
68


T2R67 (=TAS2R50 = T2R51)
69
70


T2R71 (=TAS2R41 = T2R59)
71
72


T2R75 (=TAS2R46 = T2R54)
73
74


T2R76 (=TAS2R60 = T2R56)
75
76









REFERENCES


    (1) Scott T R, Verhagen J V. Taste as a factor in the management of nutrition. Nutrition 2000 October; 16(10):874-85.
    (2) Zhao G Q, Zhang Y F, Hoon M A, Chandrashekar J, Erlenbach I, Ryba N J P, Zuker C S. The receptors for mammalian sweet and umami taste. Cell 2003 Oct. 31; 115(3):255-66.
    (3) Chandrashekar J, Hoon M A, Ryba N J, Zuker C S. The receptors and cells for mammalian taste. Nature 2006 Nov. 16; 444(7117):288-94.
    (4) Breslin P A, Spector A C. Mammalian taste perception. Curr Biol 2008 Feb. 26; 18(4):R148-R155.
    (5) Kinnamon S C, Vandenbeuch A. Receptors and transduction of umami taste stimuli. Ann N Y Acad Sci 2009 July; 1170:55-9.
    (6) Zhang F, Klebansky B, Fine R M, Xu H, Pronin A, Liu H, Tachdjian C, Li X. Molecular mechanism for the umami taste synergism. Proc Natl Acad Sci USA 2008 Dec. 30; 105(52):20930-4.
    (7) Shigemura N, Shirosaki S, Sanematsu K, Yoshida R, Ninomiya Y. Genetic and molecular basis of individual differences in human umami taste perception. PLoS One 2009; 4(8):e6717.
    (8) Li X, Staszewski L, Xu H, Durick K, Zoller M, Adler E. Human receptors for sweet and umami taste
    
        1. Proc Natl Acad Sci USA 2002 Apr. 2; 99(7):4692-6.
    
    
    (9) Ozeck M, Brust P, Xu H, Servant G. Receptors for bitter, sweet and umami taste couple to inhibitory G protein signaling pathways. European Journal of Pharmacology 2004 Apr. 12; 489(3):139-49.
    (10) Bacart J, Corbel C, Jockers R, Bach S, Couturier C. The BRET technology and its application to screening assays. Biotechnol J 2008 March; 3(3):311-24.
    (11) Pfleger K D, Dalrymple M B, Dromey J R, Eidne K A. Monitoring interactions between G-protein-coupled receptors and beta-arrestins. Biochem Soc Trans 2007 August; 35(Pt 4):764-6.
    (12) Eglen R M, Gilchrist A, Reisine T. The use of immortalized cell lines in GPCR screening: the good, bad and ugly. Comb Chem High Throughput Screen 2008 August; 11(7):560-5.
    (13) Vrecl M, Jorgensen R, Pogacnik A, Heding A. Development of a BRET2 screening assay using beta-arrestin 2 mutants. J Biomol Screen 2004 June; 9(4):322-33.
    (14) Nelson G, Hoon M A, Chandrashekar J, Zhang Y, Ryba N J, Zuker C S. Mammalian sweet taste receptors. Cell 2001 Aug. 10; 106(3):381-90.
    (15) Jiang P, Cui M, Zhao B, Snyder L A, Benard L M, Osman R, Max M, Margolskee R F. Identification of the cyclamate interaction site within the transmembrane domain of the human sweet taste receptor subunit T1R3. J Biol Chem 2005 Oct. 7; 280(40):34296-305.
    (16) Stoddart L A, Smith N J, Jenkins L, Brown A J, Milligan G. Conserved polar residues in transmembrane domains V, VI, and VII of free fatty acid receptor 2 and free fatty acid receptor 3 are required for the binding and function of short chain fatty acids. J Biol Chem 2008 Nov. 21; 283(47):32913-24.
    (17) Xu H, Staszewski L, Tang H X, Adler E, Zoller M, Li X D. Different functional roles of T1R subunits in the heterorneric taste receptors. Proceedings of the National Academy of Sciences of the United States of America 2004 Sep. 28; 101(39):14258-63.

## Claims

1. A method for identifying a compound which modulates a taste receptor, wherein the method comprises the steps of:
a) providing a cell expressing (i) a taste receptor fused to a luminescent protein and (ii) a fluorescent protein fused to a β-arrestin, wherein said taste receptor is functional such that a detectable BRET signal is present when a substance known to activate this taste receptor is added to said cell, and wherein the BRET signal is exclusively caused by specific activation of the taste receptor;
b) contacting the cell with a complex sample solution comprising a potential modulator compound and determining the BRET signal;
c) comparing the BRET signal obtained in step b) with a BRET signal obtained from the cell in the absence of the potential modulator compound, wherein a difference between the BRET signal as obtained in b) and the BRET signal obtained in the absence of the potential modulator compound, is indicative of said complex sample solution comprising a compound which modulates a taste receptor;

wherein said taste receptor is a G Protein Coupled Receptor,
wherein said complex sample solution an aqueous solution, and wherein said aqueous sample solution is a complex sample solution defined as comprising more than 10 chemically different organic molecules, and wherein the complex sample solution comprises at least one of
(a) a food product;
(b) an extract of a food product; and
(c) an extract of edible biomass; and

wherein the BRET signals are obtained in a BRET1 or BRET2 technique.

2. A method according to claim 1, wherein the extract is a tomato extract.

3. A method according to claim 1, wherein a taste receptor is selected from the group consisting of an MSG or umami receptor, a sweet receptor, a bitter receptor, a fat receptor and a nutrient/fatty acid sensing gut receptor.

4. A method according to claim 3, wherein
(a) the taste receptor is a T1R1, T1R3 heterodimer, wherein at least one of the subunits T1R1 and T1R3 is fused to a luminescent protein, and wherein a fluorescent protein is fused to a β-arrestin; or,
(b) the taste receptor is a T1R1, T1R3 heterodimer, wherein at least one of the subunits T1R1 and T1R3 is fused to a fluorescent protein, and wherein a luminescent protein is fused to a β-arrestin.

5. A method according to claim 1, wherein at least one of:
(a) the luminescent protein is a luciferase;
(b) the fluorescent protein is a GFP; and,
(e) the β-arrestin is a non-visual β-arrestin.

6. A method according to claim 5, wherein at least one of:
(a) the luciferase is a Renilla luciferase; and,
(b) the non-visual β-arrestin is a β-arrestin 2.

7. A method according to claim 1, the method comprising the further step of recovering the compound.